Impact of valproic acid on dendritic cells function

Immunobiology

Volumn 217, Issue 7, 2012, Pages 704-710

  Frikeche, Jihane ^a,b   Simon, Thomas ^b   Brissot, Eolia ^a,b   Grégoire, Marc ^a   Gaugler, Béatrice ^d,e,f   Mohty, Mohamad ^a,b,c  

^a Team 12   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Dendritic cells; HDAC inhibition; IL 12; Valproic acid

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GRANZYME B; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P70; LIPOPOLYSACCHARIDE; VALPROIC ACID;

ALLOGENEIC MIXED LYMPHOCYTE REACTION; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOCYTOTOXICITY; IMMUNOMODULATION; LEUKOCYTE CULTURE; MIXED LYMPHOCYTE REACTION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; DENDRITIC CELLS; DOWN-REGULATION; GRANZYMES; HISTONE DEACETYLASE INHIBITORS; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONOCYTES; PRIMARY CELL CULTURE; VALPROIC ACID;

EID: 84861202736     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.11.010     Document Type: Article

References (30)

1. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009, 280:233-241.
2. Bode K.A., Schroder K., Hume D.A., Ravasi T., Heeg K., Sweet M.J., Dalpke A.H. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007, 122:596-606.
3. Brogdon J.L., Xu Y., Szabo S.J., An S., Buxton F., Cohen D., Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
4. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K., Romanski A., Kramer O.H., Kampfmann M., Hoelzer D., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104:2717-2725.
5. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., Gray S.G., Imitola J., Duran G., Assaf B., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164:10-21.
6. Catley L., Weisberg E., Tai Y.T., Atadja P., Remiszewski S., Hideshima T., Mitsiades N., Shringarpure R., LeBlanc R., Chauhan D., et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003, 102:2615-2622.
7. Choi S., Reddy P. HDAC inhibition and graft versus host disease. Mol. Med. 2011, 17:404-416.
8. Choi J.H., Oh S.W., Kang M.S., Kwon H.J., Oh G.T., Kim D.Y. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 2005, 35:89-96.
9. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 2005, 45:495-528.
10. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., de la Cruz-Hernandez E., Herrera L.A. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev. 2008, 34:206-222.
11. Glauben R., Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol. Med. 2011, 17:426-433.
12. Goriely S., Neurath M.F., Goldman M. How microorganisms tip the balance between interleukin-12 family members. Nat. Rev. Immunol. 2008, 8:81-86.
13. Hilkens C.M., Kalinski P., de Boer M., Kapsenberg M.L. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997, 90:1920-1926.
14. Inoue Y., Suzuki T., Takimoto M., Irei M., Yoshioka S., Shibuya Y., Kato M., Koike M., Takahashi M. Treatment with valproic acid for myelofibrosis with myeloid metaplasia. Ann. Hematol. 2005, 84:833-834.
15. Kuendgen A., Strupp C., Aivado M., Bernhardt A., Hildebrandt B., Haas R., Germing U., Gattermann N. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004, 104:1266-1269.
16. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., Dona G., Fossati G., Sozzani S., Azam T., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:2995-3000.
17. Lyakh L., Trinchieri G., Provezza L., Carra G., Gerosa F. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol. Rev. 2008, 226:112-131.
18. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1:194-202.
19. McKenzie B.S., Kastelein R.A., Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006, 27:17-23.
20. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
21. Mostoslavsky R., Alt F.W., Bassing C.H. Chromatin dynamics and locus accessibility in the immune system. Nat. Immunol. 2003, 4:603-606.
22. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005, 6:769-776.
23. Nencioni A., Beck J., Werth D., Grunebach F., Patrone F., Ballestrero A., Brossart P. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res. 2007, 13:3933-3941.
24. Palucka A.K., Ueno H., Fay J., Banchereau J. Dendritic cells: a critical player in cancer therapy?. J. Immunother. 2008, 31:793-805.
25. Place R.F., Noonan E.J., Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem. Pharmacol. 2005, 70:394-406.
26. Reddy P., Sun Y., Toubai T., Duran-Struuck R., Clouthier S.G., Weisiger E., Maeda Y., Tawara I., Krijanovski O., Gatza E., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 2008, 118:2562-2573.
27. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994, 179:1109-1118.
28. Song W., Tai Y.T., Tian Z., Hideshima T., Chauhan D., Nanjappa P., Exley M.A., Anderson K.C., Munshi N.C. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011, 25:161-168.
29. Sun Y., Chin Y.E., Weisiger E., Malter C., Tawara I., Toubai T., Gatza E., Mascagni P., Dinarello C.A., Reddy P. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 2009, 182:5899-5903.
30. Zhou L.J., Tedder T.F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:2588-2592.